Tin tức & Cập nhật

In patients with low-risk cervical cancer, simple hysterectomy has demonstrated noninferior pelvic recurrence rate at 3 years and lower rates of surgery-related urologic adverse events (AEs) vs radical hysterectomy in the phase III, randomized, noninferiority CX.5 SHAPE trial.

Treatment with trastuzumab deruxtecan (T-DXd) provides sustained antitumour activity and shows a consistent safety profile in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC) previously treated with trastuzumab emtansine (T-DM1), as shown by the updated survival results from the phase II DESTINY-Breast01 trial.